RxDoctor Payments Data

Shaun McKenzie, MD

Surgical Oncology · Austin, TXNPI 1114189933

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,465 of the $7,702 with a category attached, or 71.0%. 16 manufacturers reported payments, led by Stryker at 26.1% of the total. Reporting peaked in 2021 at $2,468 and has fallen 51.3% since, to $1,203 in 2025.

$7,702in general payments, 2019–2025

Across 68 payments — averaging $113.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Histosonics, Inc.$2K
  • Medtronic$1K
  • Angiodynamics, Inc.$468
  • Covidien LP$385
  • Lexington Medical, Inc.$264
  • plus $1K from 10 others
$3,750in research payments, 2019–2025

Across 1 payment — averaging $3750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Histosonics, Inc.$4K

What the payments were for

  • Travel & lodging$2,23629%
  • Food & beverage$5,46571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker15$2,014
Histosonics, Inc.6$1,759
Medtronic18$1,442
Angiodynamics, Inc.4$468
Covidien LP3$385
Lexington Medical, Inc.5$264
Baxter Healthcare2$231
Boston Scientific2$187
Davol Inc.3$177
Olympus America Inc.2$154
Edwards Lifesciences1$139
Axonics, Inc.1$120
Intera Oncology, Inc1$107
Eisai Inc.1$101
Bayer1$86
Johnson & Johnson3$68

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,702 in reported general payments places this provider in the 80th percentile of 191 surgical oncology providers in Texas.

See all surgical oncology providers in Texas

Medicare billing

Part B allowed, 2024
$175,887
Medicare patients
169
Services billed
910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase16$30,489
CreonLipase/Protease/Amylase23$30,451
Ondansetron OdtOndansetron12$208
Pantoprazole Sodium16$178
Spironolactone14$157
Tramadol Hcl37$114
Celecoxib13$106
Furosemide15$49
Naproxen16$30

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →